Q-omics provides the consensus-scored GPR119 profile across patient tissues and cancer cell-line models. GPR119 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GPR119 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, GPR119 RNA expression shows 5,840 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRP, COAD, and UCEC as cancer lineages where GPR119 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR119 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR119 survival associations across molecular data types. GPR119 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR119 RNA expression–survival associations across cancer types. High GPR119 expression shows unfavorable associations in KIRP, DLBC, UCEC and COAD, but favorable associations in SKCM and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for GPR119 RNA expression.
This table summarizes GPR119 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GPR119. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR119 shows lower tumor expression in COAD, KIRP, KIRC, STAD and READ and higher tumor expression in PRAD. The COAD box plot shows higher GPR119 RNA expression in normal versus tumor tissue (log2 FC = −0.500, t-test p < 0.001).
This table shows molecular features associated with GPR119 in patient tissues and cancer cell lines. In patient samples, GPR119 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR119 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_NSCLC_LUAD.
